Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in BioScrip, Inc. to Contact th...
02 Novembre 2013 - 2:00AM
Marketwired
Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses
in Excess of $100,000 Investing in BioScrip, Inc. to Contact the
Firm
NEW YORK, NY--(Marketwired - Nov 1, 2013) - Faruqi &
Faruqi, LLP, a leading national securities law firm, reminds
investors in BioScrip, Inc. ("BioScrip" or the "Company") (NASDAQ:
BIOS) of the November 29, 2013 deadline to seek the role of lead
plaintiff in a federal securities class action lawsuit filed
against BioScrip and certain executives.
A complaint has been filed on behalf of all persons who
purchased BioScrip securities between August 8, 2011 and September
20, 2013 (the "Class Period") in the Southern District of New
York.
The complaint alleges that the Company and its executives
violated federal securities laws with respect to its disclosures
concerning its business, operations, and prospects.
Specifically, the action alleges that BioScrip issued false
and/or misleading statements concerning (i) the improper
distribution of its product Exjade through its specialty pharmacy
division and (ii) the violation of certain federal and state laws
and regulations.
On September 23, 2013, the Company announced that the U.S.
Attorney's Office for the Southern District of New York issued a
civil investigative demand and the New York State Attorney
General's Medicaid Fraud Control Unit issued a subpoena regarding
the distribution of Exjade by BioScrip's specialty pharmacy
division.
Following this news, the Company's stock declined $2.60 per
share or 23% within two trading sessions, to close at $8.47 per
share on September 24, 2013.
Request more information now by clicking here:
www.faruqilaw.com/BIOS. There is no cost or obligation to
you.
Take Action
If you invested in BioScrip stock or options between August 8,
2011 and September 20, 2013 and would like to discuss your legal
rights, visit www.faruqilaw.com/BIOS. You can also contact us
by calling Richard Gonnello or Francis McConville toll free at
877-247-4292 or at 212-983-9330 or by sending an e-mail to
rgonnello@faruqilaw.com or fmcconville@faruqilaw.com. Faruqi &
Faruqi, LLP also encourages anyone with information regarding
BioScrip's conduct to contact the firm, including whistleblowers,
former employees, shareholders and others.
Faruqi & Faruqi, LLP is a national law firm which represents
investors and individuals in class action litigation. The firm
is focused on providing exemplary legal services in complex
litigation in the areas of securities, shareholder, antitrust and
consumer litigation, throughout all phases of litigation. The
firm has an experienced trial team which has achieved significant
victories on behalf of the firm's clients. To keep track of the
latest securities litigation news, follow us on Twitter at
www.twitter.com/MergerActivity or on Facebook at
www.facebook.com/FaruqiLaw.
Attorney Advertising. The law firm responsible for this
advertisement is Faruqi & Faruqi, LLP
(www.faruqilaw.com). Prior results do not guarantee or predict
a similar outcome with respect to any future matter. We
welcome the opportunity to discuss your particular case. All
communications will be treated in a confidential manner.
FARUQI & FARUQI, LLP 369 Lexington Avenue, 10th Floor New
York, NY 10017 Attn: Richard Gonnello, Esq. Email Contact Francis
McConville, Esq. Email Contact Telephone: (877) 247-4292 or (212)
983-9330
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
BioPlus Acquisition (NASDAQ:BIOS)
Graphique Historique de l'Action
De Août 2023 à Août 2024